Regular Article
Suppressive Actions of Betaxolol on Ionic Currents in Retinal Ganglion Cells May Explain its Neuroprotective Effects

https://doi.org/10.1006/exer.2000.0822Get rights and content

Abstract

Betaxolol, a β1-selective adrenoceptor antagonist, is widely used in the treatment of glaucoma. In addition to its ocular hypotensive effects, betaxolol has been suggested to act as a retinal neuroprotective agent (27). To investigate possible mechanisms underlying the neuroprotective effects, we tested the actions of betaxolol on ion channels and calcium signaling in isolated retinal ganglion cells. Betaxolol (50 μM) reduced by about 20% the high-voltage-activated (HVA) Ca channel currents in ganglion cells isolated from tiger salamander retina. In contrast, the β1-adrenoceptor antagonists propranolol (10 μM) and timolol (50 μM) had no inhibitory actions on HVA Ca channel currents. The L -type Ca channel antagonist, nisoldipine, blocked the HVA Ca channel current partially and the remaining current was not inhibited by betaxolol. Outward current was inhibited in the presence of betaxolol. Both iberiotoxin (IBTX; 10 n M), a selective inhibitor of large-conductance Ca-activated K channels, and Cd2+(100 μM), which suppresses Ca-activated K channels subsequent to its block of Ca channels, reduced outward current and the remaining current was not blocked significantly with betaxolol. In the presence of betaxolol, Na channel currents were reduced by about 20%, as were currents evoked by glutamate (10 m M) and GABA (1 m M). Current clamp recordings from isolated ganglion cells showed that betaxolol had several effects on excitability: spike height decreased, repetitive spike activity was suppressed, spike width increased and hyperpolarization following spikes was reduced. Calcium imaging in isolated rat retinal ganglion cells revealed that betaxolol inhibited glutamate-induced increases in [Ca2+]i . These results suggest that betaxolol has a diversity of suppressive actions on ganglion cell ion channels and that, as a consequence, one of the net actions of the drug is to reduce Ca2+influx. The subsequent reduction in [Ca2+]imay contribute to the apparent neuroprotective actions of betaxolol in promoting ganglion cell survival following ischemic insult, as may occur in glaucoma and retinal disease.

References (35)

  • B.N Singh

    Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm

    Am. J. Cardiol.

    (1998)
  • L.O Trussell et al.

    Desensitization of AMPA receptors upon multiquantal neurotransmitter release

    Neuron.

    (1993)
  • R Beresford et al.

    Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension

    Drugs

    (1986)
  • T.J Campbell et al.

    Therapeutic drug monitoring: antiarrhythmic drugs

    Br. J. Clin. Pharmacol.

    (1998)
  • H.S Chen et al.

    Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity

    J. Neurosci.

    (1992)
  • D.W Choi et al.

    The role of glutamate neurotoxicity in hypoxic ischaemic death

    Annu. Rev. Neurosci.

    (1990)
  • D.L Epstein

    Medications used in chronic glaucoma therapy. Adrenergic agents: blockers and agonists

  • Cited by (46)

    • Use of calcium channel blockers for glaucoma

      2011, Progress in Retinal and Eye Research
    • Application of isoproterenol inhibits diabetic-like changes in the rat retina

      2010, Experimental Eye Research
      Citation Excerpt :

      Recent work in non-diabetic rodents demonstrated that a β-adrenergic receptor antagonist produced a significant loss of B-wave amplitude and increased angiogenic growth factors (Jiang and Steinle, 2010). Work in glaucoma has suggested that β-adrenergic receptor antagonists are neuroprotective, however, this is likely due to other effects other than β-adrenergic receptor neurotransmission (Osborne et al., 2005), such as calcium regulation (Hirooka et al., 2000). We did observe some changes in the heart histology; however, no changes in blood pressure or intraocular pressure were noted in the isoproterenol-treated animals.

    View all citing articles on Scopus
    f1

    Address correspondence to: Steven Barnes, Department of Physiology & Biophysics, Dalhousie University, Halifax, Nova Scotia B3H 4H7, Canada. E-mail: [email protected]

    f2

    Permanent address: Department of Ophthalmology, Kagawa Medical University, 1750-1, Ikenobe, Mikicho, Kagawa, Japan 761-0793.

    View full text